Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 14/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 14/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.60 |
| ▸ | CDK2 | P24941 | 13/20 | 0.60 |
| ▸ | CDK9 | P50750 | 13/20 | 0.60 |
| ▸ | CDK7 | P50613 | 13/20 | 0.60 |
| ▸ | CCNH | P51946 | 13/20 | 0.60 |
| ▸ | MNAT1 | P51948 | 10/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584307 | 1.00 | CCNK (0.60) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30359889 | 0.92 | CCNK (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL28648429 | 0.92 | CCNK (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL29583835 | 0.92 | CCNK (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL22076259 | 0.90 | CCNK (0.67) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30359967 | 0.88 | CCNK (0.47) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL29492505 | 0.88 | CDK7 (0.61) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL28817255 | 0.82 | CCNK (0.69) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL28817264 | 0.82 | CCNK (0.69) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30359979 | 0.82 | CDK2 (0.46) | CCNKCDK12CCNT1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | MEDIC LIFE SCIENCES, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20210403495-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-20210401859-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-12-30 | — | — | US | disclosed |
| CN-113677346-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3873462-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873477-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113226306-A | Methods of treating cancer in a patient identified by a biomarker using a non-covalent inhibitor of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CCNI, CDK17 | CCNK 4/4885CDK12 27/4885CCNT1 18/4885 |
| US-20210403495-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK1, CDK17 | CCNK 8/4885CDK12 30/4885CCNT1 35/4885 |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | CCNK 8/4885CDK12 30/4885CCNT1 35/4885 |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | CCNK 8/4885CDK12 30/4885CCNT1 35/4885 |
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNI | CCNK 6/4885CDK12 29/4885CCNT1 28/4885 |
| US-20210401859-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK4, RB1 | CCNK 13/4885CDK12 32/4885CCNT1 28/4885 |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | CDK7, CDK1, CDK17 | CCNK 8/4885CDK12 30/4885CCNT1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.